TELA and HUMA Show Hospital Contracting Is the New Gate

From August 10 through August 26, 2026, TELA Bio (TELA), Humacyte (HUMA), and Ambu A/S (AMBFF) described the same shift: hospital contracting, value analysis committees, and ambulatory surgery center economics increasingly determine whether a surgical product gains access and at what price.[1][2][3]

---

Hospital access now comes before physician adoption

Physician preference can create demand for a surgical product, but hospital contracts, value analysis committees, group purchasing organizations, and integrated delivery networks control whether it reaches the shelf. These committees assess clinical outcomes, price, and budget impact. A product may have regulatory approval and physician support yet still face months of review before purchasing begins. Ambulatory surgery centers add another constraint because fixed facility payments make them more price-sensitive and more interested in a broad product portfolio.

The competitive unit is therefore shifting from one product to a portfolio contract. Suppliers with established hospital relationships can add products to national agreements. Single-product vendors may need to lower prices, license commercialization, build inventory before revenue, or broaden their catalogs to obtain access. The scarce asset now includes the purchasing channel, not only the product.

---

Three suppliers are paying for channel access

TELA Bio described the authority shift most directly. OviTex unit volume rose 12% year over year while total company revenue fell 4%. Management also said decision-making authority is moving toward hospital administrators and that competitors' bundled contracts continue to obstruct OviTex adoption.[1] TELA can gain procedural share without converting all of that volume into revenue.

Humacyte showed how the access gate becomes a pricing and funding burden. The company previously said its value analysis committee approval rate was below 50% at the higher initial price and rose above 70% after a price change; committee review and contracting can take six to nine months.[2] In the second quarter of 2026, commercial sales were only $0.4 million while cost of goods sold was $1.2 million. Only $0.2 million related to units sold, with the remainder including inventory reserves and unused-capacity costs.[2]

Ambu linked pricing pressure to the migration of procedures into ambulatory surgery centers. Management said these customers want a more comprehensive portfolio, so Ambu is using strategic pricing in selected accounts at levels below its previous prices. It also said outpatient gross margins are structurally below hospital-channel margins, without quantifying the group impact.[3]

---

Access metrics may lead reported orders

As purchasing authority moves, value analysis committee approval rates, completed reviews, contracted facilities versus purchasing facilities, and sales-representative ramp time may change before revenue does. For single-product vendors, unit growth ahead of revenue, selling expenses ahead of sales, and rising inventory or idle-capacity costs can indicate the price of obtaining access. For portfolio vendors, the key test is whether existing contracts pull additional products into the same account.

Two boundaries matter. Supplier price concessions do not establish that providers have reduced supply costs: Surgery Partners' supplies rose to 26.7% of revenue from 26.0% a year earlier, which management attributed to higher implant costs from more complex procedures. Some procedure weakness may also reflect insurance disenrollment and patient affordability rather than contracting. Investors therefore need to track access conversion, revenue per unit, and provider supply costs together.

---

Companies exposed to the same purchasing shift

• Artivion (AORT): The approved Nexus system still requires value analysis committee work before its planned full US launch in January 2027, leaving it directly exposed to hospital access timelines.
• Xtant Medical (XTNT): The company is expanding its national-accounts team and covering five major orthobiologics categories to become a single-source hospital partner; its operating leverage depends on portfolio breadth opening contracts.
• Bioventus (BVS): The company cross-sells through its existing sales force and cites wins at large accounts and integrated delivery networks, so established channel access may benefit it.

Sources

[1] Drillr · TELA Bio · August 10, 2026 · FY2026 Q2 earnings call

We do see the pendulum swing in terms of decision-making authority moving more towards the administration. Having a relationship there and team members who understand what they value, being able to tell an economic value story derived from our clinical outcomes is critical to us.

[2] Drillr · Humacyte · August 12, 2026 · FY2026 Q2 earnings call and Form 10-Q

[3] Drillr · Ambu A/S · August 26, 2026 · Q3 2025/26 earnings call

This analysis identifies potentially overlooked industry changes and companies; it is not a stock recommendation.